Welcome to our dedicated page for Cue Biopharma SEC filings (Ticker: CUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cue Biopharma, Inc. filings document material events, governance actions, operating results, and capital-structure matters for a clinical-stage biopharmaceutical company focused on immune-modulating biologics. The company's 8-K reports cover executive transitions, collaboration milestones, financial results, registered common stock matters, and amendments related to a reverse stock split.
Proxy and meeting-related filings describe director elections, auditor ratification, executive compensation votes, stockholder proposal procedures, and amendments to governing documents. Other disclosures address research and development programs including CUE-401, CUE-501, the Immuno-STAT platform, collaboration and license agreements, equity compensation arrangements, and risk factors associated with clinical-stage biotechnology operations.
Cue Biopharma, Inc. director and Chief Executive Officer Shao-Lee Lin reported indirect purchases of derivative securities tied to the company’s common stock. A trust associated with Lin acquired 45,453 common stock warrants with an exercise price of $11.00 per share and 90,906 pre-funded warrants with an exercise price of $0.001 per share on June 1, 2026.
These positions were obtained under a securities purchase agreement entered on April 30, 2026, in a private placement that closed on May 4, 2026. The pre-funded warrants and accompanying warrants became exercisable on June 1, 2026, following stockholder approval of the underlying common stock issuance at the company’s Special Meeting of Stockholders in accordance with Nasdaq listing rules.
Cue Biopharma, Inc. reported results of a special stockholder meeting held on June 1, 2026. Stockholders approved the issuance of common shares upon exercise of warrants issued in May 2026 in connection with a licensing transaction and related private placement, satisfying Nasdaq Listing Rule 5635(a), (c) and (d).
They also approved the company’s 2026 Stock Incentive Plan, which will govern future equity awards to employees and other eligible participants. A proposal to allow adjournment of the meeting, if needed, was approved but ultimately not required because the main proposals received sufficient support.
Cue Biopharma, Inc. files a registration to permit resale of up to 4,090,908 shares of common stock by selling stockholders, consisting of 2,727,272 shares issuable upon exercise of Pre-Funded Warrants and 1,363,636 shares issuable upon exercise of Warrants. The company states it will not receive proceeds from resales, except for any $11.00 per-share cash exercise of the Warrants. The shares were issued in a private placement that closed on May 4, 2026; the registration implements contractual resale and registration rights and remains subject to the resale limitations and beneficial ownership caps described in the warrants.
Cue Biopharma director Viola Mong received a new stock option grant as part of her compensation. She was awarded options covering 1,626 shares of common stock at an exercise price of $21.90 per share. These options vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining two-thirds vesting in eight equal quarterly installments, aligning her incentives with the company’s long-term performance.
Cue Biopharma, Inc. filed an initial ownership report for director Meehan Viola Mong on Form 3. The filing identifies Mong as a director and not a ten percent owner, and shows no reported transactions or holdings in the summarized data.
Cue Biopharma, Inc. reported significant governance and leadership changes. On May 29, 2026, four directors — Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen — resigned from the Board and its committees, with the company stating their decisions were not due to any disagreement over operations, policies or practices.
Effective June 1, 2026, the Board appointed Sumita Ray as Chief Legal & Compliance Officer and Corporate Secretary, succeeding Colin Sandercock, who continues as Senior Vice President, Intellectual Property. The Board also named Michael Meluzio Vice President, Principal Accounting Officer, elevating him from his prior finance role without additional compensation.
On May 30, 2026, the Board appointed Daniel Camardo and Viola Meehan as directors for one-year terms and reduced the Board size from seven to five directors effective June 1, 2026. Camardo and Meehan were assigned key committee roles, including committee chair positions, and will receive cash and equity compensation under the existing Director Compensation Policy and enter into the company’s standard indemnification agreements.
Cue Biopharma is asking stockholders to approve the potential issuance of up to 4,642,632 shares of common stock upon the exercise of pre-funded warrants and warrants tied to a May 2026 licensing transaction and related private placement. These securities relate to a global (ex‑Greater China) license for Ascendant-221 and an April 30, 2026 private placement that raised approximately $30 million in gross proceeds (about $28 million net) to advance the company’s clinical pipeline and fund working capital. The warrant shares equal about 142% of the 3,266,688 shares outstanding on April 30, 2026, so approval would significantly dilute existing holders if fully exercised. Stockholders are also being asked to approve a new 2026 Stock Incentive Plan with an initial 2,327,826-share pool plus rollover and evergreen increases to restore competitive equity incentives after recent financing-related dilution. The special meeting will be held virtually on June 1, 2026 for these votes and related matters.
Cue Biopharma reported first quarter 2026 results that show sharply higher collaboration revenue and a reduced net loss, alongside important strategic and financing steps. Revenue for the quarter rose to $5.7 million from $0.4 million a year earlier, mainly from its Boehringer Ingelheim collaboration. Research and development expenses declined to $6.9 million from $8.5 million, while general and administrative costs were stable at about $4.2 million. Net loss narrowed to $5.2 million from $12.3 million, and the company reported $16.4 million in cash and cash equivalents as of March 31, 2026.
After quarter-end, Cue Biopharma completed a $30 million private placement, yielding approximately $28 million in net proceeds, and received a $7.5 million preclinical milestone payment from Boehringer Ingelheim, strengthening near-term funding. Strategically, the company licensed CUE-221, a Phase 2 anti-IgE program for allergic disease, advanced CUE-401 toward Phase 1 for autoimmune conditions, and appointed Shao-Lee Lin, M.D., Ph.D., as President and CEO to lead its transition as a clinical-stage company.
Cue Biopharma, Inc. reported first-quarter 2026 results showing sharply higher collaboration revenue and a smaller loss, while still facing going concern risks. Collaboration revenue rose to $5.7 million from $0.4 million a year earlier, driven mainly by its partnership with Boehringer Ingelheim for B‑cell depletion programs.
The company’s net loss narrowed to $5.2 million, compared with $12.3 million in the prior-year quarter, helped by lower research and development spending. Cash, cash equivalents and restricted cash were $16.5 million as of March 31 2026, after using $10.9 million in operating cash during the quarter.
Management states that accumulated deficits, ongoing losses and limited cash raise substantial doubt about the ability to continue as a going concern, though it highlights an April 2026 1‑for‑30 reverse stock split, at‑the‑market share sales, and a $27.6 million May 2026 private placement of pre‑funded and common stock warrants as key capital-raising steps. The pipeline centers on lead antibody CUE‑221 in Phase 2 for allergic diseases and autoimmune candidate CUE‑401 progressing toward Phase 1.
Cue Biopharma, Inc. is soliciting proxies for a virtual Special Meeting of stockholders to be held on June 1, 2026 to vote on three proposals. Proposal 1 asks stockholders to approve issuance of up to 4,642,632 shares upon exercise of warrants issued in May 2026 related to a licensing transaction and private placement. Proposal 2 asks approval of the 2026 Stock Incentive Plan (requesting 2,327,826 new shares plus rollover and annual increases). Proposal 3 seeks authority to adjourn the meeting if further solicitation is needed.